Literature DB >> 1888622

The comparative pharmacokinetics of acemetacin in young subjects and elderly patients.

R W Jones1, A J Collins, L J Notarianni, E Sedman.   

Abstract

Single and multiple dose pharmacokinetics of acemetacin in 10 young healthy subjects and 10 elderly patients with osteoarthritis were studied. Peak plasma concentrations of acemetacin and its metabolite, indomethacin, were found between 2.4 and 4 h after an oral dose of the drug. After dosing to steady state (7 days), the mean plasma elimination half-life for acemetacin was 1.1 h and 1.0 h, and for indomethacin 7.1 h and 7.2 h in the young and elderly groups respectively. Statistical analysis of tmax, AUC, plasma t1/2 and residual drug concentrations for acemetacin or indomethacin revealed no significant differences (P greater than 0.05) between young subjects and elderly patients after acute or chronic dosing. The results suggest that drug accumulation did not occur in the elderly subjects over the time period studied and that, on pharmacokinetic grounds, dose adjustment in the elderly is unlikely to be required.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1888622      PMCID: PMC1368473          DOI: 10.1111/j.1365-2125.1991.tb05577.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  Method for the determination of acemetacin, a non-steroidal anti-inflammatory drug, in plasma by high-performance liquid chromatography.

Authors:  L J Notarianni; A J Collins
Journal:  J Chromatogr       Date:  1987-01-23

2.  Methotrexate analogues. 30. Dihydrofolate reductase inhibition and in vitro tumor cell growth inhibition by N epsilon-(haloacetyl)-L-lysine and N delta-(haloacetyl)-L-ornithine analogues and an acivicin analogue of methotrexate.

Authors:  A Rosowsky; V C Solan; R A Forsch; T J Delcamp; D P Baccanari; J H Freisheim
Journal:  J Med Chem       Date:  1987-08       Impact factor: 7.446

3.  Rising frequency of ulcer perforation in elderly people in the United Kingdom.

Authors:  R Walt; B Katschinski; R Logan; J Ashley; M Langman
Journal:  Lancet       Date:  1986-03-01       Impact factor: 79.321

4.  [Anti-inflammatory action of acemetacin (author's transl)].

Authors:  H Jacobi; P Breier; H D Dell
Journal:  Arzneimittelforschung       Date:  1980

5.  [On the pharmacodynamics of acemetacin (author's transl)].

Authors:  H Jacobi; H D Dell
Journal:  Arzneimittelforschung       Date:  1980
  5 in total
  2 in total

1.  Mechanisms underlying the anti-inflammatory activity and gastric safety of acemetacin.

Authors:  A E Chávez-Piña; W McKnight; M Dicay; G Castañeda-Hernández; J L Wallace
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

2.  A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo.

Authors:  Rajesh Puranik; Shisan Bao; Antonio M Bonin; Ravinder Kaur; Jane E Weder; Llewellyn Casbolt; Trevor W Hambley; Peter A Lay; Philip J Barter; Kerry-Anne Rye
Journal:  Cell Biosci       Date:  2016-02-06       Impact factor: 7.133

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.